News und Analysen
Antibe Therapeutics Receives Final Approval to Graduate to the Toronto Stock Exchange
Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced
Deciphera Pharmaceuticals, Inc. to Present at the Jefferies Virtual London Healthcare Conference
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced that Steve Hoerter, President and Chief Executive Officer, will present at the Jefferies Virtual London Healthcare Conference on
True Leaf Receives Court Approval to Complete Refinancing
Vernon, BC - November 10, 2020 - True Leaf Brands Inc. (CSE: MJ) (OTC Pink: TRLFF) (FSE: TLA) (“TLB” or the “Company”) announced today that it has received approval from the British Columbia
True Leaf erhält gerichtliche Genehmigung für Abschluss der Refinanzierung
Vernon (British Columbia), 10. November 2020. True Leaf Brands Inc. (CSE: MJ) (OTCQX: TRLFF) (FWB: TLA) („TLB“ oder das „Unternehmen“) gibt heute bekannt, dass das Unternehmen die
Europäische Umfrage zeigt, dass die Qualität der Kundenreferenzdaten für die digitale Interaktion entscheidend ist
Laut einer neuen Untersuchung von Veeva Systems (NYSE: VEEV) sind Kundendaten für europäische Unternehmen der Biowissenschaften von entscheidender Bedeutung für Initiativen zur digitalen
Relay Medical Subsidiary Signs Binding LOI for Rights to COVID-19 Rapid Antigen and Antibody Tests
November 9, 2020 – Relay Medical Corp. (“Relay” or the “Company”) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2), a developer of MedTech innovation, announces that it has entered into a binding
Tochtergesellschaft von Relay Medical unterzeichnet verbindliche Absichtserklärung zum Erwerb der Rechte an COVID-19-Antigen- und Antikörper-Schnelltests
9. November 2020 – Relay Medical Corp. („Relay“ oder das „Unternehmen“) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2), ein Entwickler von Innovationen in der Medizintechnik, gibt bekannt, dass das
NANOBIOTIX Announces Positive First Clinical Data Showing Conversion of Anti-PD-1 Non-Responders to Responders With Radioenhancer NBTXR3
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext: NANO - ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today
IMV to Participate in Two Upcoming Investor Conferences
IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious
CORRECTION: TIME CHANGE - Lantheus Holdings to Present at November 2020 Investor Conferences
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB, and a global leader in the
Aurinia Presents Integrated Time to Renal Response Data from the AURA-LV and AURORA Trials, along with Voclosporin Drug-Drug Interaction Data at ACR Convergence 2020
Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH / TSX:AUP) (Aurinia or the Company), a late-stage clinical biopharmaceutical company, today announced data from an integrated analysis of the AURA-LV and
NanoString Technologies Releases Operating Results for Third Quarter of 2020
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported financial results for the third quarter of 2020.
Northwell Health, Humana Renew Agreement
Northwell Health, New York State’s largest health care provider and private employer, and Humana Inc. (NYSE: HUM), a leading health and well-being company, announced a five-year agreement that will
Transgene And BioInvent Present Data on Next Generation Oncolytic Virus BT-001 at the SITC 35th Anniversary Annual Meeting
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB
Transgene Presents E-Poster Outlining Detailed Results from the Phase 1b/2 Trial of TG4001 in Combination With Avelumab in Advanced HPV-Positive Cancers at SITC 2020
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announced the presentation of the detailed
Humana and The Humana Foundation Commit More Than $2.2 Million to COVID-19 Relief and Hurricane Recovery Efforts in Louisiana
Humana Inc. (NYSE: HUM), a leading health and well-being company, and Humana’s philanthropic arm, The Humana Foundation, have committed more than $2.2 million to COVID-19 relief and hurricane
European Survey Shows Quality Customer Reference Data Critical to Digital Engagement
According to new research from Veeva Systems (NYSE: VEEV), customer data is critical to digital transformation initiatives for European life sciences companies. Findings from the Veeva 2020
North America Survey Reveals Better Customer Data Essential to Digital Transformation
Access to quality customer reference data is more important than ever as the life sciences industry shifts to digital engagement, according to new research from Veeva Systems (NYSE: VEEV). Findings
Medigene AG: MAGE-A4-spezifische TCR-Ts von Medigene entdecken und bekämpfen Krebszellen unabhängig vom CD8 Co-Rezeptor
Poster auf dem SITC Annual Meeting 2020, 11.-14. Nov. 2020, 9:00-17:00 Uhr EST (15:00-23:00 Uhr MEZ)
Unternehmensmitteilung für den Kapitalmarkt
Planegg/Martinsried
Medigene AG: Positive Machbarkeitsdaten aus Phase-I/II-Studie - beständige, qualitativ hochwertige DC-Impfstoffe für AML-Patienten
Poster auf dem SITC Annual Meeting 2020, 11.-14. Nov. 2020, 9:00-17:00 Uhr EST (15:00-23:00 Uhr MEZ)
Unternehmensmitteilung für den Kapitalmarkt
Planegg/Martinsried
Medigene AG: Der PD1-41BB Switch-Rezeptor von Medigene verstärkt TCR-T-Zellen effektiv im Kampf gegen solide Tumore
Poster auf dem SITC Annual Meeting 2020, 11.-14. Nov. 2020, 9:00-17:00 Uhr EST (15:00-23:00 Uhr MEZ)
Unternehmensmitteilung für den Kapitalmarkt
Planegg/Martinsried (09.11.2020) - Die Med
Charles River Laboratories to Present at Upcoming Investor Conferences
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will virtually present at three upcoming investor conferences, including:
-
Credit Suisse 29th Annual Virtual
Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the SITC Annual Meeting
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced the
Xencor Presents Updated Data From the DUET-2 Phase 1 Study of XmAb20717, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported data from its
EUROIMMUN Launches Quantitative ELISA to Measure SARS-CoV-2 Antibodies Against Viral S1 Protein
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, announced today that EUROIMMUN, a PerkinElmer company, has launched the Anti-SARS-CoV-2 QuantiVacTM